An observational study in Central Core Disease, Centronuclear Myopathy and Congenital Fiber Type Disproportion, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Boston Children's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Myopathies, Structural, Congenital with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Myopathies, Structural, Congenital · United States.
Among the 13 studies in Myopathies, Structural, Congenital with a site in United States, this one is the only one that started in 2003, is one of 8 observational ones, and was the 1st registered.
24 studies on the registry are indexed under Myopathies, Structural, Congenital; 10 are open to participants now.
Browse Myopathies, Structural, Congenital studies →4 of the 13 studies in Myopathies, Structural, Congenital with a site in United States are open now. Recruiting first, the newest first:
Astellas Gene Therapies · Sites in United States, Canada
Ages up to 36 mo · Men only
Astellas Gene Therapies · Sites in United States, Canada, United Kingdom
Ages up to 17 · Men only
University of Nevada, Las Vegas · Sites in United States
Ages 18–29
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Myopathies, Structural, Congenital studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,000 is above the median of 49 across 12 observational studies indexed under Myopathies, Structural, Congenital.
Median enrollment 27 across the 5 interventional studies, 41 across the 8 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 8 most frequent:
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Boston Children's Hospital has 1 study filed under Myopathies, Structural, Congenital — fewer than ten, so there is no comparison to draw.
1 of the studies in Myopathies, Structural, Congenital with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07052929Astellas Gene TherapiesStudy of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Myopathies, Structural, Congenital with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In the Congenital Myopathy Research Program at Boston Children's Hospital and Harvard Medical School, the researchers are studying the congenital myopathies (neuromuscular diseases present from birth), including central core disease, centronuclear/myotubular myopathy, congenital fiber type disproportion, multiminicore disease, nemaline myopathy, rigid spine muscular dystrophy, SELENON (SEPN1), RYR1 myopathy, ADSS1 (ADSSL) Myopathy and undefined congenital myopathies. The primary goal of the research is to better understand the genes and proteins (gene products) involved in muscle functioning and disease. The researchers hope that our studies will allow for improved diagnosis and treatment of individuals with congenital myopathies in the future. For more information, visit the Laboratory Website at www.childrenshospital.org/research/beggs
The Congenital Myopathy Research Program consists of a group of scientists and healthcare providers all working to better understand the congenital myopathies. We are taking two approaches to reach our research goals. The first involves identifying and describing new genes and proteins involved in the skeletal muscles that allow our bodies to move. Simultaneously, studies are underway to identify genetic changes (mutations) that cause human neuromuscular disease. Thus, our second approach is to identify mutations, learn how they are inherited in families, and understand how they lead to weakness in individuals with neuromuscular disease. These approaches allow correlation of our basic muscle biology findings with our studies on muscle tissue of affected individuals.
Our research would not be possible without the generous participation of individuals and families with congenital myopathies. Participation in our studies is free of charge. Travel to Boston is not required, and we welcome the participation of individuals from around the world.
We appreciate the participation of all individuals with a congenital myopathy, as well as their first-degree relatives. Participants with a congenital myopathy are asked to donate medical records, a blood or saliva sample, and a muscle tissue sample (if available). Participating relatives are asked to donate a blood sample. The blood/saliva sample is used to acquire DNA (genetic material) which can be used to identify genetic changes and to study how a disease is inherited in a family. The medical records are employed to understand a participant's symptoms. The muscle tissue is used to better understand the disease at the muscular level by studying the gene expression and protein levels in individuals with congenital myopathies.
For more information, visit the Laboratory Website at www.childrenshospital.org/research/beggs.
Individuals with a clinical or suspected diagnosis of a congenital myopathy and their family members.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Identification of Neuromuscular Disease Genes
This is an ongoing genetic discovery study aimed at finding and confirming pathogenic mutations in known and new disease genes.
Time frame: The time frame for disease gene discovery is unpredictable and may range from several days to several decades.
Characterization of Clinical Features of Congenital Myopathies
As known as known and new disease genes are identified the resulting genotypes are correlated with subject phenotypes.
Time frame: The time frame for disease classification and genotype-phenotype correlation is unpredictable and may range from several days to several decades.
The record gives a start of Aug 2003, a primary completion of Jan 2050 and a completion of Jan 2050. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myopathies, Structural, Congenital →